TKT's Replagal Fails Phase III; Genzyme Still Mum On Its Data
As Transkaryotic Therapies Inc. revealed a weak hand regarding Replagal (agalsidase alfa), all eyes turned to competitor Genzyme General, which has been playing its cards close to the vest. (Bioworld Today)